Rep. Josh Gottheimer bought Sarepta Therapeutics (SRPT)
Rep. Josh Gottheimer (D-NJ-5) · $1K–$15K · traded Jul 14, 2023
- Transaction
- Bought
- Amount
- $1K–$15K
- Owner
- Joint
- Traded
- Jul 14, 2023
- Disclosed
- Aug 21, 2023
- Days to disclose
- 38
- Asset type
- Stock
- As filed
- Sarepta Therapeutics, Inc.
- Industry
- Biotechnology · Healthcare
Other trades in this filing
All of Gottheimer's trades →- Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 27, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
Sold (partial) Freeport-McMoRan FCX
$1K–$15K · Traded Jul 25, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
Bought Advanced Micro Devices AMD
$1K–$15K · Traded Jul 24, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 21, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 20, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
Sold (partial) AIA Group Limited AAGIY
$1K–$15K · Traded Jul 20, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 20, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 20, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 19, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 19, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 19, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
Sold (partial) AIA Group Limited AAGIY
$1K–$15K · Traded Jul 19, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 19, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 19, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 18, 2023 · disclosed Aug 21, 2023 · Joint
Got $4K from the company’s PAC - Aug 21, 2023$1K–$15K
Sold (partial) Lithia Motors LAD
$1K–$15K · Traded Jul 18, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
Sold (partial) The Charles Schwab SCHW
$1K–$15K · Traded Jul 18, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 18, 2023 · disclosed Aug 21, 2023 · Joint
- Aug 21, 2023$1K–$15K
Sold (partial) Meta Platforms META
$1K–$15K · Traded Jul 18, 2023 · disclosed Aug 21, 2023 · Joint
Got $4K from the company’s PAC - Aug 21, 2023$1K–$15K
$1K–$15K · Traded Jul 18, 2023 · disclosed Aug 21, 2023 · Joint
Recent Congress trades in SRPT
- May 6, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Sold Sarepta Therapeutics SRPT
$1K–$15K · Traded Apr 14, 2025 · disclosed May 6, 2025
- Jul 11, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold Sarepta Therapeutics SRPT
$1K–$15K · Traded Jun 13, 2023 · disclosed Jul 11, 2023 · Joint
- May 19, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Sold Sarepta Therapeutics SRPT
$15K–$50K · Traded Apr 10, 2023 · disclosed May 19, 2023
- Apr 20, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Bought Sarepta Therapeutics SRPT
$1K–$15K · Traded Mar 6, 2023 · disclosed Apr 20, 2023 · Joint
- Apr 17, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Bought Sarepta Therapeutics SRPT
$15K–$50K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
- Feb 24, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
Sold Sarepta Therapeutics SRPT
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
Company context for SRPT
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
SRPT: third_quarter 2026 lobbying report
H.R. 9260 - LHHS Appropriations Rare Pediatric Disease Priority Review Voucher (PRV) Program Issues related to patient access to treatment National Security Commission on emerging biotechnology policy proposals Issues related to Section 232
Public: Oct 19, 2026, 4:58 PM EDTOriginal source ↗SRPT: second_quarter 2026 lobbying report
H.R. 9260 - LHHS Appropriations H.R. 1509 - Accelerating Kids Access to Care Act Patient Access Act Issues related to patient access to treatment National Security Commission on emerging biotechnology policy proposals Issues related to supply chain Issues related to Section 232
Public: Jul 20, 2026, 1:40 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.